NASDAQ:NVCT Nuvectis Pharma (NVCT) Stock Price, News & Analysis $17.55 +1.02 (+6.17%) Closing price 06/23/2026 04:00 PM EasternExtended Trading$17.88 +0.32 (+1.85%) As of 06/23/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Nuvectis Pharma Stock (NASDAQ:NVCT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Nuvectis Pharma alerts:Sign Up Key Stats Today's Range$15.89▼$18.2450-Day Range$8.33▼$17.5552-Week Range$5.55▼$18.24Volume280,928 shsAverage Volume111,684 shsMarket Capitalization$465.60 millionP/E RatioN/ADividend YieldN/APrice Target$39.00Consensus RatingHold Company Overview Nuvectis Pharma is a clinical-stage biotechnology company focused on the development of novel peptide-based therapeutics using its proprietary Cellporting delivery platform. The company’s core technology is designed to facilitate the transport of therapeutic proteins and peptides across cellular membranes and into target intracellular compartments, including the nucleus. By overcoming a key barrier in biologics delivery, Nuvectis aims to expand the range of treatable diseases with macromolecular drugs that have traditionally been limited by poor cellular uptake. The Nuvectis pipeline encompasses multiple preclinical and early-stage clinical programs targeting rare genetic and metabolic disorders. Lead candidates are being evaluated for inherited conditions characterized by enzyme deficiencies or receptor dysfunction, with the goal of delivering active protein payloads directly to affected cells. In parallel, the company is exploring applications of its delivery technology in areas such as oncology and inflammatory disease, seeking strategic partnerships to advance select programs into later clinical development. Headquartered in San Diego, California, Nuvectis Pharma operates with a management team drawn from established life-science and pharmaceutical backgrounds. The company maintains research collaborations with academic centers and contract development organizations to accelerate its discovery and development activities. With a focus on rare diseases and high-unmet-need patient populations, Nuvectis is positioning its platform to address therapeutic challenges that extend beyond the reach of conventional biologic and small-molecule approaches. AI Generated. May Contain Errors. Read More Nuvectis Pharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks46th Percentile Overall ScoreNVCT MarketRank™: Nuvectis Pharma scored higher than 46% of companies evaluated by MarketBeat, and ranked 508th out of 850 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingHold Consensus RatingNuvectis Pharma has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.Upside PotentialNuvectis Pharma has a consensus price target of $39.00, representing about 122.2% upside from its current price of $17.55.Amount of Analyst CoverageNuvectis Pharma has only been the subject of 2 research reports in the past 90 days.Read more about Nuvectis Pharma's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Nuvectis Pharma are expected to grow in the coming year, from ($1.01) to ($0.98) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Nuvectis Pharma is -13.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Nuvectis Pharma is -13.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNuvectis Pharma has a P/B Ratio of 24.38. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Nuvectis Pharma's valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted8.34% of the float of Nuvectis Pharma has been sold short.Short Interest Ratio / Days to CoverNuvectis Pharma has a short interest ratio ("days to cover") of 13.62, which indicates bearish sentiment.Change versus previous monthShort interest in Nuvectis Pharma has recently increased by 10.82%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNuvectis Pharma does not currently pay a dividend.Dividend GrowthNuvectis Pharma does not have a long track record of dividend growth. News and Social Media3.7 / 5News Sentiment0.94 News SentimentNuvectis Pharma has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Nuvectis Pharma this week, compared to 2 articles on an average week.MarketBeat Follows1 people have added Nuvectis Pharma to their MarketBeat watchlist in the last 30 days. Company Ownership1.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Nuvectis Pharma insiders have not sold or bought any company stock.Percentage Held by Insiders28.55% of the stock of Nuvectis Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions96.77% of the stock of Nuvectis Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Nuvectis Pharma's insider trading history. Receive NVCT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nuvectis Pharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NVCT Stock News HeadlinesNuvectis Lands Major Haisco Deal for Two Potentially Best-in-Class Compounds in Multi-Billion-Dollar MarketsJune 23 at 12:35 PM | theglobeandmail.comNuvectis Pharma jumps 20% to 52-week high — here's why NVCT stock is trendingJune 23 at 7:35 AM | msn.comA drilling crew just broke a record nobody expectedA drilling crew in Beaver County, Utah hit 15,765 feet of solid granite in 16 days - a job the Department of Energy projected would take 64. They reached DOE's 2035 performance targets twelve years early, cutting costs in half within 18 months. When Congress moved to cut solar and wind tax credits, this energy source kept its full credits through 2033. One company has been building in this space for sixty years, and a July 4th catalyst is now 12 days away. | Behind the Markets (Ad)Nuvectis Expands Pipeline with Haisco Licensing Agreement for Two Clinical-Stage Drug Candidates (NVCT)June 22 at 9:34 PM | finance.yahoo.comNuvectis Pharma, Inc. (NVCT) Discusses Strategic In-Licensing Deal and Expansion Into Complement-Mediated Diseases and Oncology Prepared Remarks TranscriptJune 22 at 12:06 PM | seekingalpha.comNuvectis gains two experimental drugs in licensing deal with China's HaiscoJune 22 at 8:34 AM | reuters.comNuvectis Pharma Expands Pipeline with Exclusive Ex-China Rights to Haisco’s NXP100 and NXP200 Clinical-Stage CandidatesJune 22 at 7:51 AM | quiverquant.comQNuvectis Announces Strategic Portfolio Expansion via License Agreement for Ex-China Rights with Haisco Pharmaceutical Group for Two Potentially Best-In Class Clinical-Stage ...June 22 at 7:49 AM | markets.businessinsider.comSee More Headlines NVCT Stock Analysis - Frequently Asked Questions How have NVCT shares performed this year? Nuvectis Pharma's stock was trading at $7.55 at the beginning of 2026. Since then, NVCT stock has increased by 132.5% and is now trading at $17.55. How were Nuvectis Pharma's earnings last quarter? Nuvectis Pharma, Inc. (NASDAQ:NVCT) announced its quarterly earnings results on Tuesday, May, 5th. The company reported ($0.26) EPS for the quarter, topping analysts' consensus estimates of ($0.30) by $0.04. When did Nuvectis Pharma IPO? Nuvectis Pharma (NVCT) raised $19 million in an initial public offering on Friday, February 4th 2022. The company issued 3,200,000 shares at a price of $5.00-$7.00 per share. Who are Nuvectis Pharma's major shareholders? Top institutional shareholders of Nuvectis Pharma include Bank of New York Mellon Corp (0.11%) and Bank of America Corp DE (0.06%). Insiders that own company stock include Marlio Charles Mosseri, Enrique Poradosu, Matthew L Kaplan and Juan Sanchez. View institutional ownership trends. How do I buy shares of Nuvectis Pharma? Shares of NVCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Nuvectis Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Nuvectis Pharma investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Invesco QQQ (QQQ), Tesla (TSLA), Meta Platforms (META), JPMorgan Chase & Co. (JPM) and Netflix (NFLX). Company Calendar Last Earnings5/05/2026Today6/23/2026Next Earnings (Estimated)8/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (6m+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 NVCT's financial health is in the Green zone, according to TradeSmith. NVCT has been in this zone for over 6 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:NVCT CIK1875558 Webwww.nuvectis.com Phone201-614-3150FaxN/AEmployees8Year Founded2020Price Target and Rating Average Price Target for Nuvectis Pharma$39.00 High Price Target$39.00 Low Price Target$39.00 Potential Upside/Downside+122.2%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($1.31) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$26.44 million Net MarginsN/A Pretax MarginN/A Return on Equity-161.00% Return on Assets-98.88% Debt Debt-to-Equity RatioN/A Current Ratio2.27 Quick Ratio2.27 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.72 per share Price / Book24.38Miscellaneous Outstanding Shares26,530,000Free Float18,953,000Market Cap$465.60 million OptionableNot Optionable Beta-0.07 Social Links Analysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NASDAQ:NVCT) was last updated on 6/24/2026 by MarketBeat.com Staff. From Our PartnersQuick favor to ask youBill Poulos is giving away his 'Safe Trade Options Formula' book at no charge - the same book that sells for $...Profits Run | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | SponsoredTop Banks Warn: A Strange Day is Coming to AmericaGoldman Sachs and Morgan Stanley are warning clients about a developing crisis that could suppress portfolio g...TradeSmith | SponsoredA drilling crew just broke a record nobody expectedA drilling crew in Beaver County, Utah hit 15,765 feet of solid granite in 16 days - a job the Department of E...Behind the Markets | SponsoredBlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely, LLC | SponsoredRead this before you touch SPCXSPCX is live on Nasdaq - but a market expert who called AMD before it climbed as high as 7,100% says buying th...Altimetry | SponsoredElon Musk, Larry Fink & Brian Armstrong are ALL Piling into ThisElon Musk, BlackRock CEO Larry Fink, and Coinbase CEO Brian Armstrong are all quietly investing in the same te...Brownstone Research | SponsoredKarp just filed Form 144On May 12, 2026, Palantir CEO Alex Karp filed to sell 585,000 shares - roughly $95.93 million. Combined with f...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nuvectis Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nuvectis Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
